Skip to content
value.today

Vivani Medical, Inc.

VANI
$121 Mmarket cap on Aug 1, 2026+120.0% since Jan 2024
Compare
World rank
#18,053
Revenue
—
For year ending December-2025
Net income
$-27 M
SEC filing
Employees
36
As of December 31, 2025
SEC filing

Vivani Medical, Inc. in brief

Vivani Medical, Inc. is a listed company in the Medical Devices industry, based in Alameda, California, USA. Its market value was $121 M on 1 August 2026, which makes it the 18,053rd largest listed company in the world and the 3,420th largest in the USA on this site. It employs about 36 people and Adam Mendelsohn is its chief executive. Its shares trade under the symbol VANI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Vivani Medical, Inc.

Vivani Medical, Inc. is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address leading causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients.

From the company's annual report filed with the US SEC: read the report

Vivani Medical, Inc. timeline

5 events, 2003–2025
  1. 2003
  2. ✎
    Renamed Second Sight Medical Products Inc
    Formerly Secound Sight Medical Products Inc.
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2014
  5. 🔔
    · approximate
    Initial public offering on Nasdaq
  6. 2022
  7. ✎
    Renamed Vivani Medical, Inc.
    Formerly Second Sight Medical Products Inc.
  8. 2025
  9. 💰
    Record net income of $27 million
    FY2025, the highest profit of the 3 years on record.

Events of Vivani Medical, Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$33 M$65 M$98 M$131 M2023202420252026

World rank over time

▲ up 8,736 places since 2022
2022-12-25: #25563#25,56320222023-07-30: #24054#24,05420232024-01-05: #24462#24,46220242026-03-08: #10105#10,10520262026-08-01: #16827#16,8272026

Rank in USA: #4,836 (Dec 2022) · #4,575 (Jul 2023) · #4,016 (Jan 2024) · #1,957 (Mar 2026) · #3,336 (Aug 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
7.7×
Free cash flow yield
-21.1%
Net margin
—
Operating margin
—
Return on equity
-169.2%
Liabilities / assets
60.1%
Revenue growth
-51.0%
R&D / revenue
388.8%
Profit per employee
$-739 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $8M, net income $-29M$8MFY17Fiscal year ending Dec 2018: revenue $7M, net income $-35M$7MFY18Fiscal year ending Dec 2019: revenue $3M, net income $-34M$3MFY19Fiscal year ending Dec 2020: revenue —, net income $-15M—FY20Fiscal year ending Dec 2022: revenue —, net income $-14M—FY22Fiscal year ending Dec 2023: revenue —, net income $-26M—FY23Fiscal year ending Dec 2024: revenue —, net income $-23M—FY24Fiscal year ending Dec 2025: revenue —, net income $-27M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-28M$-27M—
Dec 2024——$-25M$-23M—
Dec 2023——$-27M$-26M—
Dec 2022——$-21M$-14M—
Dec 2020——$-15M$-15M—
Dec 2019$3M-51.0%$-34M$-34M-993.8%
Dec 2018$7M-13.3%$-35M$-35M-508.6%
Dec 2017$8M—$-29M$-29M-358.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-24M$1M$-25M$-0.43—
Dec 2024$-21M$1M$-21M$-0.43—
Dec 2023$-24M$1M$-25M$-0.50—
Dec 2022$-19M$0M$-19M——
Dec 2020$-17M$0M$-17M$-0.72—
Dec 2019$-28M$0M$-28M$-2.28—
Dec 2018$-30M$0M$-30M$-4.23—
Dec 2017$-24M$0M$-24M$-0.53—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-6M—Mar ’25Three months to Jun 2025: revenue —, net income $-7M—Jun ’25Three months to Sep 2025: revenue —, net income $-7M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-7M—Dec ’25Three months to Mar 2026: revenue —, net income $-7M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue —, net income $-7M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Vivani Medical, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-28 M
Net income
$-27 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$39 M
Total liabilities
$24 M
Total equity
$16 M

As of December-2025

Top 38 institutional investors in Vivani Medical, Inc.#

As of Sep 30, 2026
38 institutions held 4.7 M shares (about 5.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Vivani Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC1,437,373-330,704 (-18.70%)1.59%$2 MNov 13, 2026
2Tanager Wealth Management LLP607,2760 (0.00%)0.67%$1 MOct 19, 2026
3Geode Capital Management, LLC518,622-69,123 (-11.76%)0.57%$1 MNov 6, 2026
4Commonwealth Equity Services, LLC320,565-10,000 (-3.03%)0.36%$0 MNov 2, 2026
5BlackRock, Inc.293,187-8,641 (-2.86%)0.33%$0 MNov 13, 2026
6Vanguard Fiduciary Trust Co232,318-93,144 (-28.62%)0.26%$0 MNov 13, 2026
7Monetary Management Group Inc193,9770 (0.00%)0.21%$0 MNov 16, 2026
8Susquehanna International Group, LLP155,779+127,433 (+449.56%)0.17%$0 MNov 16, 2026
9State Street Corp154,9650 (0.00%)0.17%$0 MNov 12, 2026
10Jane Street Group, LLC122,343New0.14%$0 MNov 12, 2026
11Northern Trust Corp116,9070 (0.00%)0.13%$0 MNov 16, 2026
12Arax Advisory Partners100,000New0.11%$0 MNov 12, 2026
13MAI Capital Management99,8700 (0.00%)0.11%$0 MNov 12, 2026
14Millennium Management LLC70,730New0.08%$0 MNov 16, 2026
15Citadel Advisors LLC54,758New0.06%$0 MNov 16, 2026
16Gsa Capital Partners LLP54,146-6,720 (-11.04%)0.06%$0 MNov 16, 2026
17Armstrong Advisory Group, Inc25,000-20,000 (-44.44%)0.03%$0 MOct 9, 2026
18Schonfeld Strategic Advisors LLC19,000New0.02%$0 MNov 16, 2026
19Vanguard Global Advisers, LLC16,2790 (0.00%)0.02%$0 MNov 13, 2026
20Focus Partners Wealth16,144New0.02%$0 MNov 12, 2026
21StoneX Group Inc.15,369+1,226 (+8.67%)0.02%$0 MNov 3, 2026
22Marshall Wace, LLP11,1610 (0.00%)0.01%$0 MNov 13, 2026
23Lazari Capital Management, Inc.10,0000 (0.00%)0.01%$0 MOct 20, 2026
24Simplex Trading, LLC3,787New0.00%$0 MNov 4, 2026
25Steward Partners Investment Advisory, LLC2,0000 (0.00%)0.00%$0 MNov 13, 2026
Show all 38: investors 26 to 38
Institutional investors 26 to 38 in Vivani Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jpmorgan Chase & Co1,662-1,727 (-50.96%)0.00%$0 MNov 12, 2026
27Jones Financial Companies Lllp1,2000 (0.00%)0.00%$0 MNov 13, 2026
28SBI Securities Co., Ltd.1,165+1 (+0.09%)0.00%$0 MOct 22, 2026
29Rothschild Investment LLC1,000New0.00%$0 MNov 10, 2026
30Pinnacle Financial Group, Inc.796—0.00%$0 MNov 16, 2026
31Osaic Holdings, Inc.2200 (0.00%)0.00%$0 MNov 12, 2026
32UBS Group AG202-50,906 (-99.60%)0.00%$0 MNov 10, 2026
33NFSG Corp1030 (0.00%)0.00%$0 MOct 15, 2026
34Highland Investment Advisors LLC320 (0.00%)0.00%$0 MNov 9, 2026
35Caitong International Asset Management Co., Ltd13+7 (+116.67%)0.00%$0 MOct 29, 2026
36Barclays PLC11-652 (-98.34%)0.00%$0 MNov 6, 2026
37Danske Bank A/s10 (0.00%)0.00%$0 MNov 9, 2026
38Morgan Stanley1-9 (-90.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Vivani Medical, Inc.#

10 funds hold shares worth $3 M (about 2.6% of the company). Since their previous reports 6 added shares and 3 sold, buying $0 M net.
Mutual funds holding Vivani Medical, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.11 M$1 M1.2%<0.01%+31%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.643,786$1 M0.71%<0.01%−0.3%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC283,769$0 M0.31%<0.01%+14%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors133,707$0 M0.15%0.01%+2.7%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC69,679$0 M0.08%<0.01%+13%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC58,567$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC47,626$0 M0.05%<0.01%+27%May 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.13,244$0 M0.01%<0.01%−63%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC8,403$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,637$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 10 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Vivani Medical, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$16.8 M
19 purchases, 3 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$16.8 M
open market only
Insiders on file
22
since
$8.0 M$0Nov 2023: bought $14 K (8 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $171 K (12 trades), sold $0 (0 trades)Jan 2024: bought $44 K (11 trades), sold $0 (0 trades)Feb 2024: bought $5 K (5 trades), sold $0 (0 trades)FebJul 2024: bought $11 K (2 trades), sold $0 (0 trades)Oct 2024: bought $3 K (3 trades), sold $0 (0 trades)Nov 2024: bought $5.0 M (1 trades), sold $0 (0 trades)NovFeb 2025: bought $1 K (1 trades), sold $0 (0 trades)Apr 2025: bought $259 K (13 trades), sold $0 (0 trades)May 2025: bought $13 K (3 trades), sold $0 (0 trades)MaySep 2025: bought $2.4 M (2 trades), sold $0 (0 trades)Oct 2025: bought $8.0 M (3 trades), sold $0 (0 trades)Nov 2025: bought $2.0 M (2 trades), sold $0 (0 trades)NovDec 2025: bought $2.0 M (3 trades), sold $0 (0 trades)Jan 2026: bought $4.0 M (3 trades), sold $0 (0 trades)Feb 2026: bought $2.0 M (2 trades), sold $0 (0 trades)FebMar 2026: bought $1.7 M (2 trades), sold $0 (0 trades)Apr 2026: bought $2.0 M (1 trades), sold $0 (0 trades)May 2026: bought $2.0 M (1 trades), sold $0 (0 trades)MayJun 2026: bought $2.0 M (1 trades), sold $0 (0 trades)Jul 2026: bought $1000 K (1 trades), sold $0 (0 trades)Nov 2026: bought $101 K (5 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Vivani Medical, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gregg WilliamsDirector, 10% ownerBuyindirect+29,929$1.051$31 K36.99 MForm 4
filed Gregg WilliamsDirector, 10% ownerBuyindirect+2,100$1.010$2 K36.96 MForm 4
filed Gregg WilliamsDirector, 10% ownerBuyindirect+48,100$0.993$48 K36.96 MForm 4
filed Donald DwyerChief Business OfficerBuy+5,000$0.830$4 K60,000Form 4
filed Donald DwyerChief Business OfficerBuy+15,000$1.033$15 K75,000Form 4
filed Aaron MendelsohnDirectorGift-20,000——168,170Form 4
filed Gregg WilliamsDirector, 10% ownerBuyindirect+793,650$1.260$1000 K36.91 MForm 4
filed Gregg WilliamsDirector, 10% ownerBuyindirect+1.59 M$1.260$2.0 M36.12 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vivani Medical, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
369,789
0.5% of shares · 2.03 days to cover
Buybacks, Q1 2015
$0.1M
Q1 2015
Shares sold short, last 24 reportsAll stocks →

Stock splits: 8-for-1 split

Vivani Medical, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q1 2015Q1 2015$0.1M

Fails to deliver

  • : 73,147 shares at $1.38
  • : 73,147 shares at $1.38
  • : 73,147 shares at $1.41
  • : 74,250 shares at $1.39
  • : 238,815 shares at $1.35

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vivani Medical, Inc. scorecard#

Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.43 vs -0.43Diluted EPS -0.43 in fiscal 2025 against -0.43 the year before (report's currency).
    • ✗Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$15 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-159.6%-159.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.7×Current ratio 2.71 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year13.5%Diluted shares up 13.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Vivani Medical, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Vivani Medical, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue00————3.46.98.04.0
Cost of revenue————0.10.52.24.95.110
Gross profit————0.10.51.22.02.8−6.1
Research and development1816171411r4.813107.95.3
Selling and marketing—————0.76.1119.69.0
General and administrative9.48.910.07.12.3r5.99.2111110
Operating expenses2825272113r1535373127
Operating income−28−25−27−21−13r−15−34−35−29−33
Other non-operating income (expense)0.91.21.3———————
Income before tax−27−23————————
Income tax—0.0————00——
Net income attributable to shareholders−27−23−26−14−13r−15−34−35−29−33
Earnings per share, basic-0.43-0.43-0.50—-0.27-0.72-2.28-4.23r-0.53-0.84
Earnings per share, diluted-0.43-0.43-0.50—-0.27-0.72-2.28-4.23r-0.53-0.84
Shares, weighted average (basic)6255r0.1———————
Shares, weighted average (diluted)6255r0.1—3321158.3r5440r
Balance sheet
Cash and cash equivalents161821452.2r2.1r114.57.8r11r
Receivables——————0.50.51.80.3
Inventory——————1.03.32.73.4
Other current assets1.01.82.42.50.3r1.10.31.40.80.7
Current assets182023482.5r4.3139.61315
Loans to customers (net)————————00.0
Property, plant and equipment2.91.71.71.21.2r0.21.11.01.31.5
Right-of-use (leased) assets1718200.81.6r—2.3———
Total assets394246515.5r4.517111417
Accounts payable1.00.80.51.20.3r0.51.11.30.81.2
Debt due within a year—————2.2————
Current liabilities6.66.05.76.82.1r5.17.07.66.65.7
Lease liabilities (non-current)171819—0.9r—2.4———
Total liabilities2424256.83.0r5.19.37.6——
Retained earnings−149−122−98−73−59r−320−305−269−234−206
Shareholders' equity161821442.5r2.0r7.3r3.17.911
Total equity————————7.911
Total liabilities and equity394246515.5r4.517111417
Shares outstanding765951r0.1r37r0.0r169.5r58r43r
Cash-flow statement
Depreciation and amortization0.40.40.40.40.3r0.20.40.40.50.4
Share-based compensation1.51.61.91.31.7r0.42.93.63.83.4
Cash from operating activities−24−21−24−19−11r−17−28−30−24−25
Capital expenditure−1.2−0.6−0.9−0.3−0.6r−0.3−0.5−0.2−0.3−0.5
Cash from investing activities−1.2−0.6−0.9−0.3−0.6r0.1−0.5−0.2−0.3r−0.5r
Shares issued———————262119
Cash from financing activities23190.16312r8.635272120
Exchange-rate effect on cash————0.00.0−0.00.00.0r0.0r
Change in cash−2.1−2.3−24440.1r−8.26.9−3.4−3.0r−5.1r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Vivani Medical, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$878 K
Adam Mendelsohn
Other top executives, average
$751 K
the CEO earned 1.2× this
$100 invested is now
$145
Vivani Medical, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Adam Mendelsohn$878 K$857 K$751 K$145
2024Adam Mendelsohn$1.1 M$915 K$770 K$137
2023Adam Mendelsohn$1.0 M$955 K$694 K$120

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Vivani Medical, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 6 · Unregistered share sale 5 · Shareholder vote 2 · Results announced 9

Vivani Medical, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementUnregistered share saleResults announced8-K
Results announced8-K
Material agreementUnregistered share sale8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Vivani Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$28 MPrivate placement after listing$10 to $50 million7equitySEC
Dec 2018$3 MPrivate placement after listing$2 to $10 million2equitySEC
Oct 2018$4 MPrivate placement after listing$2 to $10 million2equitySEC
Aug 2018$5 MPrivate placement after listing$2 to $10 million2equitySEC
May 2018$10 MPrivate placement after listing$10 to $50 million1equitySEC
Sep 2013$11 MNo. 5$10 to $50 million5equitySEC
Aug 2013$6 MNo. 4$2 to $10 million—equitySEC
Feb 2012$2 MNo. 3$2 to $10 million—equitySEC
Dec 2011$2 MNo. 2$2 to $10 million—equitySEC
Nov 2009$5 MNo. 1$2 to $10 million19equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Vivani Medical, Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $95 K a year.

Certified, FY2024
1
#1,967 among companies on value.today
Worker positions
1
Median wage offered
$95 K
a year, full-time
Applications filed
1
Vivani Medical, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Chemist IIChemists1$95 K

Where: Alameda, CA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Vivani Medical, Inc.

Layoffs at Vivani Medical, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
8
2018–2018
Latest
8 people
2018-10-09
Vivani Medical, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2018·········8··8
Vivani Medical, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
8 peopleRestructuring planSEC 8-K“Specifically, the Company will reduce expenses and personnel by 8 employees related to international commercial operations for the Argus ® II Retinal Prosthesis System (“Argus II”)…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Vivani Medical, Inc. compares in Medical Devices

  • Market cap$121 M · higher than 37% of 142
  • Revenue growth-51.0% · higher than 3% of 104
  • Price / book7.7× · lower than 18% of 99
  • FCF yield-21.1% · higher than 27% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Vivani Medical, Inc.🇺🇸$121 M——-51.0%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Aug 1, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vivani Medical, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vivani Medical, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vivani Medical, Inc.? Suggest a correction